Table 3 Treatments and outcomes of COVID-19 patients with Different BMI

 Acute respiratory distress syndrome

7(2.6%)

15(8.0%)

0.008

 liver function abnormality

41(15.3%)

50(26.7%)

0.003

 Acute kidney injury

0(0.0%)

0(0.0%)

 Shock

0(0.0%)

1(0.5%)

0.411

 Antiviral treatment (n (%))

267(99.6%)

187(100%)

0.403

  Days from illness onset to antiviral therapy (days)

5(3–8)

5(3–8)

0.926

  Days of antiviral therapy

16(13–21)

18(14–23)

0.001

 Antiviral regimen (days)

0.731

  Interferon-α + Lopinavir/Ritonavir + arbidol

159(59.6%)

120(64.2%)

  Interferon-α + Lopinavir/Ritonavir

45(16.9%)

27(14.4%)

  Interferon-α + arbidol

19(7.1%)

13(7.0%)

  Lopinavir/Ritonavir+arbidol

33(12.4%)

18(9.6%)

  Others^a

11(4.1%)

9(4.8%)

  Antibiotic therapy

128(47.8%)

108(57.8%)

0.036

  Use of corticosteroid

44(16.4%)

45(24.1%)

0.043

  Use of immunoglobulin

43(16.0%)

44(23.5%)

0.046

  mechanical ventilation

2(0.7%)

6(3.2%)

0.109

  CRRT

0(0.0%)

0(0.0%)

  ECMO

1(0.4%)

0(0.0%)

1.000

  Admission to intensive care unit

1(0.4%)

2(1.1%)

0.753

 Days from illness onset to SARS-CoV-2 RNA negative (days)

17(13–21)

18(14–25)

0.015

 Days of hospitalization (days)

17(13–22)

19(15–24)

0.003

 Days from illness onset to discharge (days)

21(17–26)

23(18–29)

0.008

 Days of fever (days)

9(6–12)

9(6–12)

0.939

 Days from first abnormal imaging findings to obvious absorption (days)

13(10–17)

13(10–16)

0.115